PBAC's latest decision on Methoxsalen: Recommended (2021). Considered for Treatment of steroid dependent, steroid intolerant or steroid refractory chronic graft versus host disease (cGVHD) in patients following allogeneic haematopoietic stem cell transplantation, as part of treatment with integrated, closed system extracorporeal photopheresis (ECP).
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
4
first 2017
Submissions
4
2017 → 2021
Eligible population
Patients with steroid dependent, steroid intolerant or steroid refractory chronic graft versus host disease (cGVHD) following allogeneic haematopoietic stem cell transplantation, receiving integrated closed system extracorporeal photopheresis (ECP).
Therapy area
Haematology
Line of therapy
Second-line
Evidence base
Single-arm
Primary endpoint
Response
Comparator
current standard of care, which consists of the continued use of steroids from first-line treatment, in combination with mycophenolate mofetil or calcineurin inhibitors
Economic model
Not modelled
ICER note
The submission is co-dependent with an MBS-listed procedure (ECP). The PBAC notes that the medicine component is substantially smaller in overall scope and financial implications compared to the procedure component. The comparative efficacy and economic analysis was to be considered by MSAC, not PBAC. No ICER is stated in the PBAC PSD.